NexImmune (NexImmune) Short-Term Capital Lease Obligation : $0.07 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NexImmune Short-Term Capital Lease Obligation?

NexImmune's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.07 Mil.

NexImmune's quarterly Short-Term Capital Lease Obligation declined from Jun. 2023 ($0.55 Mil) to Sep. 2023 ($0.50 Mil) and declined from Sep. 2023 ($0.50 Mil) to Dec. 2023 ($0.07 Mil).

NexImmune's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.60 Mil) but then declined from Dec. 2022 ($0.60 Mil) to Dec. 2023 ($0.07 Mil).

NexImmune Short-Term Capital Lease Obligation Historical Data

The historical data trend for NexImmune's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexImmune Short-Term Capital Lease Obligation Chart

NexImmune Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.60

0.07

NexImmune Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial														0.60	0.59	0.55	0.50	0.07

NexImmune Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

NexImmune Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of NexImmune's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

NexImmune (NexImmune) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NexImmune Inc (NAS:NEXI) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

9119 Gaither Road, Gaithersburg, MD, USA, 20877

Website

https://www.neximmune.com

NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

Executives

Alan S. Roemer	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Timothy Stover	officer: VP, Corporate Controller	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Sol J Barer	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Zhengbin Yao	director	10301 STELLA LINK ROAD, HOUSTON TX 77025
Leena Gandhi	director	C/O NEXIMMUNE, 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Timothy Bertram	director	C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Paul D'angio	director	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Grant Verstandig	director	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Mathias Oelke	officer: Chief Science Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Kristi Jones	officer: Chief Operating Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Jerome B Zeldis	officer: EVP of R&D	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Scott Carmer	director, officer: President and CEO	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
John Trainer	officer: Chief Financial Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Robert Douglas Knight	officer: Chief Medical Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877